Navigation Links
Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
Date:11/18/2009

RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.

Data were presented in a student course at the University of Pennsylvania School of Medicine from a single subject treated with SB-728-T who, as part of the study, began a structured treatment interruption (STI) from his antiviral drug therapy four weeks after SB-728-T treatment. This subject was reported to have stable CD4+ and ZFN-modified T-cell levels and an undetectable viral load one month post STI initiation. Previous studies have shown that in subjects undergoing an STI, the average time to detection of an increase in viral load is two to four weeks. While this subject continues to demonstrate stable CD4+ T-cell counts and stable levels of ZFN-modified T-cells, by six weeks post STI initiation the subject had a detectable viral load.

As previously stated, the company and the University of Pennsylvania intend to provide updates on the two ongoing Phase 1 SB-728-T trials only at appropriate scientific or medical meetings.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused o
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
2. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
3. Sangamo Announces Pricing of Public Offering of Common Stock
4. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
5. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
6. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
7. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
10. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
11. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , Switzerland , ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ , ... drugs that target unmet medical needs as ... preclinical data on the investigational compounds Debio 1143 ... will be presented at the 2015 Annual ...
(Date:4/16/2015)... 2015 Fairleigh Dickinson University ( ... to become the Executive Director of the Rothman ... the kick-off of the Initiative for Patient Centered ... Gulfo, under the Rothman Institute of Innovation and ... in collaboration with FDU’s School of Pharmacy’s Center ...
(Date:4/16/2015)... 2015 Dana-Farber Cancer Institute and ... Resolution Bioscience, Inc. today announced the successful completion ... blood-based, clinic ready, Next Generation Sequencing (NGS) assay ... is the first to demonstrate the successful sequencing ... in blinded plasma samples and highlights the ability ...
(Date:4/16/2015)... California (PRWEB) April 16, 2015 CCI ... incentives, MDF and joint planning management software for major ... its latest industry benchmark survey of channel vendor programs ... explores:, How the top IT ... now and through the coming year. , ...
Breaking Biology Technology:Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3
... Inc. (Microbia), an emerging leader in the production ... technology, has announced that Mike Doyle has joined ... manager of nutrition ingredients. Mike is the ... and will lead Microbia,s food ingredients business initiatives. ...
... HOUSTON, April 2 US Oncology , ... US Oncology Clinical Development (USOCD), a ... formalizes many of the services that US Oncology ... For more than a decade US Oncology Research has offered ...
... Intercell,s IXIARO, the first licensed vaccine against Japanese ... -- This final decision follows the positive opinion ... in December 2008VIENNA, April 2 Intercell AG ... to prevent Japanese Encephalitis, IXIARO(R), has been approved ...
Cached Biology Technology:Microbia, Inc. Names Mike Doyle as Senior Vice President and General Manager, Nutrition Ingredients 2Microbia, Inc. Names Mike Doyle as Senior Vice President and General Manager, Nutrition Ingredients 3US Oncology Provides Full Service Management of Clinical Trials 2US Oncology Provides Full Service Management of Clinical Trials 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 2Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 4
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... increasingly common sight at airports and on loading ... evaluate suspicious packages. A new test material developed ... (NIST) in cooperation with ASTM International enables users ... reliability. The new testing material, NIST Standard ...
... Researchers at Weill Cornell Medical College have shown that it ... their technique could possibly be used on other mammals -- ... species-non-specific and are similar in both females and males. For ... adverse effects of hormone administration. In the Feb. 24 ...
... and Forest Degradation ,Plus, (REDD+) is a climate ... landowners and stewards for "avoiding" forest loss and ... forest management and the enhancement of forest carbon ... the potential to generate a valuable stream of ...
Cached Biology News:NIST, ASTM land a one-two punch to fight explosives terrorism 2Immune therapy can control fertility in mammals 2REDD+, Technical, Socioeconomic and Political Dimensions 2REDD+, Technical, Socioeconomic and Political Dimensions 3
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Self Closing Forceps...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... 8 micro-bore tubes to 1 outflow ... tips, Rapid (several millisecond) solution change ... prevention , Solid construction 360, 250 ... For mounting on any micromanipulator Available ...
Biology Products: